Novo: Type 2 diabetes patients benefit from early Victoza therapy

09/13/2011 | Reuters

Novo Nordisk said a large number of patients with type 2 diabetes who received early treatment with Victoza met a target level for blood glucose compared with those treated later, according to data presented at a conference of the European Association for the Study of Diabetes. Early use of Victoza also led to greater clinical benefit and improved beta-cell function, the drugmaker reported.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA